Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g...
Saved in:
Main Authors: | C. J. J. Mulder, S. J. Van Den Hazel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
1998-01-01
|
Series: | Mediators of Inflammation |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09629359891027 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
by: Hongzhen Wu, et al.
Published: (2025-01-01) -
Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
by: Ronghui Li, et al.
Published: (2025-01-01) -
Modern Approaches in the Morphological Diagnosis of Inflammatory Bowel Diseases
by: A. S. Tertychnyy, et al.
Published: (2022-08-01) -
Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01) -
The Influence of Physical Activity on Inflammatory Markers, Intestinal Microbiota Composition and Disease Activity in Inflammatory Bowel Disease
by: Paulina Jakubczyk, et al.
Published: (2025-01-01)